POPULARITY
13 episodes with tanios bekaii saab
3 episodes with tanios bekaii saab
4 episodes with tanios bekaii saab
2 episodes with tanios bekaii saab
Featuring perspectives from Dr Tanios Bekaii-Saab and Dr Philip A Philip, including the following topics: Introduction (0:00) Colorectal Cancer, Anal Cancer and Pancreatic Cancer — Dr Philip (1:56) Gastroesophageal Cancers, Hepatocellular Cancer and Biliary Tract Cancers — Dr Bekaii-Saab (41:48) CME information and select publications
Dr Tanios Bekaii-Saab from Mayo Clinic in Phoenix, Arizona, and Dr Philip A Philip from the Henry Ford Cancer Institute in Detroit, Michigan, discuss recent research presentations on the treatment of gastrointestinal cancers.
Dr Tanios Bekaii-Saab from Mayo Clinic in Phoenix, Arizona, and Dr Philip A Philip from the Henry Ford Cancer Institute in Detroit, Michigan, discuss recent research presentations on the treatment of gastrointestinal cancers.
Dr Tanios Bekaii-Saab from Mayo Clinic in Phoenix, Arizona, and Dr Philip A Philip from the Henry Ford Cancer Institute in Detroit, Michigan, discuss recent research presentations on the treatment of gastrointestinal cancers.
Dr Tanios Bekaii-Saab from Mayo Clinic in Phoenix, Arizona, and Dr Philip A Philip from the Henry Ford Cancer Institute in Detroit, Michigan, discuss recent research presentations on the treatment of gastrointestinal cancers, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/PostESMO24/GI).
Featuring perspectives from Dr Tanios Bekaii-Saab and Dr John Strickler, including the following topics: Introduction: Back-to-School Special (0:00) Biomarker Assays in Advanced Gastrointestinal (GI) Cancers (10:12) Sequencing of Treatment for HER2-Positive GI Cancers (28:37) Toxicities Associated with Anti-HER2 Treatment (48:32) Novel Agents and Strategies for HER2-Positive GI Cancers (58:10) CME information and select publications
Inside the Issue: Integrating HER2-Targeted Strategies into the Management of Gastrointestinal Cancers | Faculty Presentation 2: Emerging Role of HER2-Targeted Therapy in Advanced Biliary Tract Cancers (BTCs) — Tanios Bekaii-Saab, MD CME information and select publications
Dr Tanios Bekaii-Saab from the Mayo Clinic Cancer Center in Phoenix, Arizona, and Dr John Strickler from Duke University in Durham, North Carolina, review clinical data supporting the application of HER2-targeted therapies for patients with gastrointestinal cancers.
Dr Tanios Bekaii-Saab from the Mayo Clinic Cancer Center in Phoenix, Arizona, and Dr John Strickler from Duke University in Durham, North Carolina, review clinical data supporting the application of HER2-targeted therapies for patients with gastrointestinal cancers.
Dr Tanios Bekaii-Saab from the Mayo Clinic Cancer Center in Phoenix, Arizona, and Dr John Strickler from Duke University in Durham, North Carolina, review clinical data supporting the application of HER2-targeted therapies for patients with gastrointestinal cancers.
Dr Tanios Bekaii-Saab from the Mayo Clinic Cancer Center in Phoenix, Arizona, and Dr John Strickler from Duke University in Durham, North Carolina, review clinical data supporting the application of HER2-targeted therapies for patients with gastrointestinal cancers, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/InsideTheIssue2024/HER2GI).
In this podcast episode from the Oncology Brothers delve into the needs of different patient populations in colorectal cancer. Joined by Dr. Tanios Bekaii-Saab, a medical oncologist, and Ms. Deneen Richmond, a patient advocate, nurse, and the President of the Doctors Community Medical Center, the discussion highlights disparities in access to colorectal cancer screening and treatments among various communities. Deneen shares her personal journey as a patient, emphasizing the importance of trust and being heard in healthcare. The episode also explores strategies to raise awareness and educate different patient groups, including leveraging trusted voices and community outreach. Tune in for valuable insights on understanding and addressing the diverse needs of patients in colorectal cancer care.
In this ASCO-GI research special, Dr. Bekaii-Saab of Mayo Clinic provides an insightful and comprehensive roundup of the most groundbreaking studies unveiled at the ASCO GI 2024 meeting. Delving into the realm of hepatocellular carcinoma, he dissects the pivotal previously-reported data from IMbrave050 and ASCO GI findings from EMERALD-1. Then, he sheds light on developments in colorectal cancer, exploring the impact of KEYNOTE-177 and CheckMate 8HW. Moreover, Dr. Bekaii-Saab explores the latest advancements in minimal residual disease assessment with a focus on studies like BESPOKE and GALAXY, as well as the prognostic value of ctDNA assessment showcased in COBRA. Check out Chadi's website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/ Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA
Featuring perspectives from Dr Tanios Bekaii-Saab, Dr Andrea Cercek, Dr Cathy Eng and Dr John Strickler, moderated by Dr Christopher Lieu, including the following topics: Introduction (0:00) Optimizing Biomarker Assessment and Treatment for Patients with Metastatic Colorectal Cancer (mCRC) — Dr Eng (2:48) Emerging Role of Biomarker-Based Decision-Making for Patients with Localized CRC — Dr Lieu (28:14) Identification and Clinical Care of Patients with mCRC and a BRAF V600E Mutation — Dr Bekaii-Saab (51:20) Integration of Immune Checkpoint Inhibitors into the Management of Microsatellite Instability-High/Mismatch Repair-Deficient mCRC — Dr Cercek (1:14:34) HER2 and Other Emerging Biomarkers for Targeted Therapy in mCRC — Dr Strickler (1:35:48) CME information and select publications
Featuring perspectives from Dr Tanios Bekaii-Saab, Dr Harold Burstein, Dr Asher Chanan-Khan, Dr Komal Jhaveri, Dr Brad S Kahl, Dr Alicia K Morgans, Dr Philip A Philip, Dr Gregory J Riely, Dr Matthew R Smith and Dr Heather Wakelee, including the following topics: Introduction (0:00) ER-Positive Breast Cancer — Dr Burstein (3:57) Clinical Questions and Cases (16:47) Selection and Sequencing of Treatment for Relapsed ER-Positive Metastatic Breast Cancer — Dr Jhaveri (33:32) Clinical Questions and Cases (46:02) CME information and select publications
Featuring perspectives from Dr Tanios Bekaii-Saab, Dr Harold Burstein, Dr Asher Chanan-Khan, Dr Komal Jhaveri, Dr Brad S Kahl, Dr Alicia K Morgans, Dr Philip A Philip, Dr Gregory J Riely, Dr Matthew R Smith and Dr Heather Wakelee, including the following topics: Introduction (0:00) Chronic Lymphocytic Leukemia (CLL): Considerations for Front-Line Treatment — Dr Kahl (1:48) Treatment of Relapsed/Refractory CLL; Novel and Investigational Strategies — Dr Chanan-Khan (35:38) Clinical Questions and Cases (49:58) CME information and select publications
Featuring perspectives from Dr Tanios Bekaii-Saab, Dr Harold Burstein, Dr Asher Chanan-Khan, Dr Komal Jhaveri, Dr Brad S Kahl, Dr Alicia K Morgans, Dr Philip A Philip, Dr Gregory J Riely, Dr Matthew R Smith and Dr Heather Wakelee, including the following topics: Introduction (0:00) Gastroesophageal Cancers — Dr Philip (1:42) Colorectal Cancer — Dr Bekaii-Saab (32:56) CME information and select publications
Featuring perspectives from Dr Tanios Bekaii-Saab, Dr Harold Burstein, Dr Asher Chanan-Khan, Dr Komal Jhaveri, Dr Brad S Kahl, Dr Alicia K Morgans, Dr Philip A Philip, Dr Gregory J Riely, Dr Matthew R Smith and Dr Heather Wakelee, including the following topics: Introduction (0:00) Non-Small Cell Lung Cancer Targeted Therapy — Dr Riely (4:09) Non-Small Cell Lung Cancer: Immunotherapeutic and Other Novel Strategies — Dr Wakelee (32:23) CME information and select publications
Featuring perspectives from Dr Tanios Bekaii-Saab, Dr Harold Burstein, Dr Asher Chanan-Khan, Dr Komal Jhaveri, Dr Brad S Kahl, Dr Alicia K Morgans, Dr Philip A Philip, Dr Gregory J Riely, Dr Matthew R Smith and Dr Heather Wakelee, including the following topics: Introduction (0:00) Role of Hormonal Therapy in Prostate Cancer Management — Dr Smith (1:50) Clinical Questions and Cases (13:18) Evidence-Based Use of Other Therapeutic Approaches in Metastatic Castration-Resistant Prostate Cancer — Dr Morgans (26:08) Clinical Questions and Cases (38:01) CME information and select publications
Dr Tanios Bekaii-Saab from the Mayo Clinic in Phoenix, Arizona, discusses the role of novel therapeutic management approaches for patients with colorectal and gastroesophageal cancers, moderated by Dr Neil Love. Produced by Research To Practice.
Dr Tanios Bekaii-Saab from the Mayo Clinic in Phoenix, Arizona, discusses the role of novel therapeutic management approaches for patients with colorectal and gastroesophageal cancers, moderated by Dr Neil Love. Produced by Research To Practice.
Dr Tanios Bekaii-Saab from the Mayo Clinic in Phoenix, Arizona, discusses the role of novel therapeutic management approaches for patients with colorectal and gastroesophageal cancers, moderated by Dr Neil Love. Produced by Research To Practice.
Dr Tanios Bekaii-Saab from the Mayo Clinic in Phoenix, Arizona, discusses the role of novel therapeutic management approaches for patients with colorectal and gastroesophageal cancers. NCPD information and select publications here (https://www.researchtopractice.com/ONS2023GE/AudioInterview)
Please visit answersincme.com/MPP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, two experts—a medical oncologist and an oncology nurse practitioner—discuss a multidisciplinary approach to holistic management of hand-foot skin reaction (HFSR) from multikinase inhibitor therapy in patients with colorectal cancer (CRC). Upon completion of this activity, participants should be better able to: Recognize the impact of hand-foot skin reaction (HFSR) in patients being treated with multikinase inhibitors; Discuss the rationale for holistic management of HFSR in patients taking multikinase inhibitors; and Outline strategies for optimal HFSR management, including patient education and practical shared communication strategies to help manage HFSR.
Tanios Bekaii-Saab, MD - Expert Perspectives on Treatment Sequencing in Advanced CRC: Keys to Reaching Later Lines of Therapy
Tanios Bekaii-Saab, MD - Expert Perspectives on Treatment Sequencing in Advanced CRC: Keys to Reaching Later Lines of Therapy
Tanios Bekaii-Saab, MD - Expert Perspectives on Treatment Sequencing in Advanced CRC: Keys to Reaching Later Lines of Therapy
Tanios Bekaii-Saab, MD - Expert Perspectives on Treatment Sequencing in Advanced CRC: Keys to Reaching Later Lines of Therapy
Tanios Bekaii-Saab, MD - Expert Perspectives on Treatment Sequencing in Advanced CRC: Keys to Reaching Later Lines of Therapy
Tanios Bekaii-Saab, MD - Expert Perspectives on Treatment Sequencing in Advanced CRC: Keys to Reaching Later Lines of Therapy
Tanios Bekaii-Saab, MD - Expert Perspectives on Treatment Sequencing in Advanced CRC: Keys to Reaching Later Lines of Therapy
Tanios Bekaii-Saab, MD - Expert Perspectives on Treatment Sequencing in Advanced CRC: Keys to Reaching Later Lines of Therapy
Proceedings from a daylong symposium hosted in partnership with North Carolina Oncology Association and the South Carolina Oncology Society, featuring key clinical presentations and papers in breast cancer, gastrointestinal cancers, genitourinary cancers, chronic lymphocytic leukemia and lymphomas, gynecologic cancers and lung cancer. Featuring perspectives from Drs Tanios Bekaii-Saab, Michael Birrer, Danielle Brander, Harold Burstein, Ibiayi Dagogo-Jack, Virginia Kaklamani, Stephen Liu, Ursula Matulonis, Rutika Mehta, Craig Moskowitz, Daniel Petrylak and Sandy Srinivas.
Proceedings from a daylong symposium hosted in partnership with North Carolina Oncology Association and the South Carolina Oncology Society, featuring key clinical presentations and papers in breast cancer, gastrointestinal cancers, genitourinary cancers, chronic lymphocytic leukemia and lymphomas, gynecologic cancers and lung cancer. Featuring perspectives from Drs Tanios Bekaii-Saab, Michael Birrer, Danielle Brander, Harold Burstein, Ibiayi Dagogo-Jack, Virginia Kaklamani, Stephen Liu, Ursula Matulonis, Rutika Mehta, Craig Moskowitz, Daniel Petrylak and Sandy Srinivas.
Proceedings from a daylong symposium hosted in partnership with North Carolina Oncology Association and the South Carolina Oncology Society, featuring key clinical presentations and papers in breast cancer, gastrointestinal cancers, genitourinary cancers, chronic lymphocytic leukemia and lymphomas, gynecologic cancers and lung cancer. Featuring perspectives from Drs Tanios Bekaii-Saab, Michael Birrer, Danielle Brander, Harold Burstein, Ibiayi Dagogo-Jack, Virginia Kaklamani, Stephen Liu, Ursula Matulonis, Rutika Mehta, Craig Moskowitz, Daniel Petrylak and Sandy Srinivas.
Please visit answersincme.com/ERJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, two experts, one in oncology and another in dermatology, discuss strategies for diagnosis and management of hand-foot skin reaction. Upon completion of this activity, participants should be better able to: Recognize hand-foot skin reaction (HFSR) in patients being treated with multikinase inhibitors; Discuss the rationale for comprehensive management of HFSR in patients taking multikinase inhibitors; and Outline strategies for optimal HFSR management, including patient education to promote self-management.
Please visit answersincme.com/ERJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, two experts, one in oncology and another in dermatology, discuss strategies for diagnosis and management of hand-foot skin reaction. Upon completion of this activity, participants should be better able to: Recognize hand-foot skin reaction (HFSR) in patients being treated with multikinase inhibitors; Discuss the rationale for comprehensive management of HFSR in patients taking multikinase inhibitors; and Outline strategies for optimal HFSR management, including patient education to promote self-management.
Featuring perspectives from Drs Tanios Bekaii-Saab, Kristen Ciombor, Eileen O'Reilly, Philip Philip, John Strickler and Prof Eric Van Cutsem, including the following topics: Introduction (0:00) Integration of targeted therapy and immunotherapy into the management of metastatic colorectal cancer — Kristen K Ciombor, MD, MSCI (3:15) Other considerations in the management of early and advanced colorectal cancer — John Strickler, MD (33:15) Current and future treatment paradigm for gastroesophageal cancers — Eric Van Cutsem, MD, PhD (55:26) Selection and sequencing of therapy for advanced hepatocellular carcinoma — Philip A Philip, MD, PhD, FRCP (1:23:00) Novel treatment strategies for advanced biliary tract cancers — Tanios Bekaii-Saab, MD (1:50:31) CME information and select publications
This week, CancerNetwork turns to the second part of its 3-part series focused on colorectal cancer. Tanios Bekaii-Saab, MD, a gastrointestinal cancers (GI) medical oncologist at the Mayo Clinic Cancer Center, continues the conversation with Kristen Ciombor, MD, MSCI, a GI medical oncologist and associate professor of medicine at Vanderbilt-Ingram Cancer Center, and John Strickler, MD, a GI medical oncologist, associate professor of medicine, and co-leader of the Molecular Tumor Board at Duke University School of Medicine. This episode's discussion turns to the GOZILA platform and its international collaboration. The experts expand on this platform, what it means for drug development, and examine genetic testing in GI malignancies. Tune in next week for the third and final part of this conversation on colorectal cancer. Don't forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.
This week, CancerNetwork looks at the final part of its 3-part series focused on colorectal cancer. Tanios Bekaii-Saab, MD, a gastrointestinal cancers (GI) medical oncologist at the Mayo Clinic Cancer Center, concludes his conversation with Kristen Ciombor, MD, MSCI, a GI medical oncologist and associate professor of medicine at Vanderbilt-Ingram Cancer Center, and John Strickler, MD, a GI medical oncologist, associate professor of medicine, and co-leader of the Molecular Tumor Board at Duke University School of Medicine. This conversation focuses on resistance to targeted therapies in metastatic colorectal cancer, and the importance of addressing it. The experts also discuss EGFR resistance, EGFR rechallenging after prior progression, and rising HER2 amplification. Thanks for tuning in to this series on colorectal cancer from CancerNetwork. Visit cancernetwork.com to catch up on any episodes you missed and to read more about these topics published in the journal ONCOLOGY. Don't forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.
This week, CancerNetwork kicks off the first of a 3-part podcast series focused on colorectal cancer. Tanios Bekaii-Saab, MD, a gastrointestinal cancers (GI) medical oncologist at the Mayo Clinic Cancer Center, leads a conversation with Kristen Ciombor, MD, MSCI, a GI medical oncologist and associate professor of medicine at Vanderbilt-Ingram Cancer Center, and John Strickler, MD, a GI medical oncologist, associate professor of medicine, and co-leader of the Molecular Tumor Board at Duke University School of Medicine. This conversation focuses on the current molecular treatment landscape of advanced colorectal cancer and the need for the COLOMATE platform. Among other things, the experts detail this platform and expand on its impact for patients, as well as the evolving world of colorectal cancer. Make sure to tune in next week for part 2 of this conversation on colorectal cancer. Don't forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.
PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
Go online to PeerView.com/GVA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Successfully and safely delivering optimized care in metastatic colorectal cancer (mCRC) can be a challenge, particularly during later lines of therapy and when managing patients exposed to many prior therapies. Current evidence shows that these challenges can be overcome—including through the optimized delivery of novel agents, enhanced dosing strategies, and AE mitigation approaches. To learn more, join CRC expert, Dr. Tanios Bekaii-Saab, as he navigates through different team-based treatment strategies designed to improve the delivery of later-line care in patients with mCRC. Upon completion of this activity, participants should be better able to: Summarize recent evidence regarding dosage optimization of third-line treatments for metastatic colorectal cancer (mCRC), Implement alternative dose strategies based on the latest data to maximize third-line therapeutic efficacy in mCRC, Integrate interprofessional team-based approaches to improve patient adherence and education on prevention and management strategies for adverse events associated with third-line TKI-based therapies for mCRC.
Go online to PeerView.com/GVA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Successfully and safely delivering optimized care in metastatic colorectal cancer (mCRC) can be a challenge, particularly during later lines of therapy and when managing patients exposed to many prior therapies. Current evidence shows that these challenges can be overcome—including through the optimized delivery of novel agents, enhanced dosing strategies, and AE mitigation approaches. To learn more, join CRC expert, Dr. Tanios Bekaii-Saab, as he navigates through different team-based treatment strategies designed to improve the delivery of later-line care in patients with mCRC. Upon completion of this activity, participants should be better able to: Summarize recent evidence regarding dosage optimization of third-line treatments for metastatic colorectal cancer (mCRC), Implement alternative dose strategies based on the latest data to maximize third-line therapeutic efficacy in mCRC, Integrate interprofessional team-based approaches to improve patient adherence and education on prevention and management strategies for adverse events associated with third-line TKI-based therapies for mCRC.
Go online to PeerView.com/GVA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Successfully and safely delivering optimized care in metastatic colorectal cancer (mCRC) can be a challenge, particularly during later lines of therapy and when managing patients exposed to many prior therapies. Current evidence shows that these challenges can be overcome—including through the optimized delivery of novel agents, enhanced dosing strategies, and AE mitigation approaches. To learn more, join CRC expert, Dr. Tanios Bekaii-Saab, as he navigates through different team-based treatment strategies designed to improve the delivery of later-line care in patients with mCRC. Upon completion of this activity, participants should be better able to: Summarize recent evidence regarding dosage optimization of third-line treatments for metastatic colorectal cancer (mCRC), Implement alternative dose strategies based on the latest data to maximize third-line therapeutic efficacy in mCRC, Integrate interprofessional team-based approaches to improve patient adherence and education on prevention and management strategies for adverse events associated with third-line TKI-based therapies for mCRC.
Go online to PeerView.com/GVA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Successfully and safely delivering optimized care in metastatic colorectal cancer (mCRC) can be a challenge, particularly during later lines of therapy and when managing patients exposed to many prior therapies. Current evidence shows that these challenges can be overcome—including through the optimized delivery of novel agents, enhanced dosing strategies, and AE mitigation approaches. To learn more, join CRC expert, Dr. Tanios Bekaii-Saab, as he navigates through different team-based treatment strategies designed to improve the delivery of later-line care in patients with mCRC. Upon completion of this activity, participants should be better able to: Summarize recent evidence regarding dosage optimization of third-line treatments for metastatic colorectal cancer (mCRC), Implement alternative dose strategies based on the latest data to maximize third-line therapeutic efficacy in mCRC, Integrate interprofessional team-based approaches to improve patient adherence and education on prevention and management strategies for adverse events associated with third-line TKI-based therapies for mCRC.
Go online to PeerView.com/GVA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Successfully and safely delivering optimized care in metastatic colorectal cancer (mCRC) can be a challenge, particularly during later lines of therapy and when managing patients exposed to many prior therapies. Current evidence shows that these challenges can be overcome—including through the optimized delivery of novel agents, enhanced dosing strategies, and AE mitigation approaches. To learn more, join CRC expert, Dr. Tanios Bekaii-Saab, as he navigates through different team-based treatment strategies designed to improve the delivery of later-line care in patients with mCRC. Upon completion of this activity, participants should be better able to: Summarize recent evidence regarding dosage optimization of third-line treatments for metastatic colorectal cancer (mCRC), Implement alternative dose strategies based on the latest data to maximize third-line therapeutic efficacy in mCRC, Integrate interprofessional team-based approaches to improve patient adherence and education on prevention and management strategies for adverse events associated with third-line TKI-based therapies for mCRC.
Go online to PeerView.com/GVA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Successfully and safely delivering optimized care in metastatic colorectal cancer (mCRC) can be a challenge, particularly during later lines of therapy and when managing patients exposed to many prior therapies. Current evidence shows that these challenges can be overcome—including through the optimized delivery of novel agents, enhanced dosing strategies, and AE mitigation approaches. To learn more, join CRC expert, Dr. Tanios Bekaii-Saab, as he navigates through different team-based treatment strategies designed to improve the delivery of later-line care in patients with mCRC. Upon completion of this activity, participants should be better able to: Summarize recent evidence regarding dosage optimization of third-line treatments for metastatic colorectal cancer (mCRC), Implement alternative dose strategies based on the latest data to maximize third-line therapeutic efficacy in mCRC, Integrate interprofessional team-based approaches to improve patient adherence and education on prevention and management strategies for adverse events associated with third-line TKI-based therapies for mCRC.
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
Go online to PeerView.com/GVA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Successfully and safely delivering optimized care in metastatic colorectal cancer (mCRC) can be a challenge, particularly during later lines of therapy and when managing patients exposed to many prior therapies. Current evidence shows that these challenges can be overcome—including through the optimized delivery of novel agents, enhanced dosing strategies, and AE mitigation approaches. To learn more, join CRC expert, Dr. Tanios Bekaii-Saab, as he navigates through different team-based treatment strategies designed to improve the delivery of later-line care in patients with mCRC. Upon completion of this activity, participants should be better able to: Summarize recent evidence regarding dosage optimization of third-line treatments for metastatic colorectal cancer (mCRC), Implement alternative dose strategies based on the latest data to maximize third-line therapeutic efficacy in mCRC, Integrate interprofessional team-based approaches to improve patient adherence and education on prevention and management strategies for adverse events associated with third-line TKI-based therapies for mCRC.
Go online to PeerView.com/GVA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Successfully and safely delivering optimized care in metastatic colorectal cancer (mCRC) can be a challenge, particularly during later lines of therapy and when managing patients exposed to many prior therapies. Current evidence shows that these challenges can be overcome—including through the optimized delivery of novel agents, enhanced dosing strategies, and AE mitigation approaches. To learn more, join CRC expert, Dr. Tanios Bekaii-Saab, as he navigates through different team-based treatment strategies designed to improve the delivery of later-line care in patients with mCRC. Upon completion of this activity, participants should be better able to: Summarize recent evidence regarding dosage optimization of third-line treatments for metastatic colorectal cancer (mCRC), Implement alternative dose strategies based on the latest data to maximize third-line therapeutic efficacy in mCRC, Integrate interprofessional team-based approaches to improve patient adherence and education on prevention and management strategies for adverse events associated with third-line TKI-based therapies for mCRC.
Go online to PeerView.com/GVA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Successfully and safely delivering optimized care in metastatic colorectal cancer (mCRC) can be a challenge, particularly during later lines of therapy and when managing patients exposed to many prior therapies. Current evidence shows that these challenges can be overcome—including through the optimized delivery of novel agents, enhanced dosing strategies, and AE mitigation approaches. To learn more, join CRC expert, Dr. Tanios Bekaii-Saab, as he navigates through different team-based treatment strategies designed to improve the delivery of later-line care in patients with mCRC. Upon completion of this activity, participants should be better able to: Summarize recent evidence regarding dosage optimization of third-line treatments for metastatic colorectal cancer (mCRC), Implement alternative dose strategies based on the latest data to maximize third-line therapeutic efficacy in mCRC, Integrate interprofessional team-based approaches to improve patient adherence and education on prevention and management strategies for adverse events associated with third-line TKI-based therapies for mCRC.
Go online to PeerView.com/GVA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Successfully and safely delivering optimized care in metastatic colorectal cancer (mCRC) can be a challenge, particularly during later lines of therapy and when managing patients exposed to many prior therapies. Current evidence shows that these challenges can be overcome—including through the optimized delivery of novel agents, enhanced dosing strategies, and AE mitigation approaches. To learn more, join CRC expert, Dr. Tanios Bekaii-Saab, as he navigates through different team-based treatment strategies designed to improve the delivery of later-line care in patients with mCRC. Upon completion of this activity, participants should be better able to: Summarize recent evidence regarding dosage optimization of third-line treatments for metastatic colorectal cancer (mCRC), Implement alternative dose strategies based on the latest data to maximize third-line therapeutic efficacy in mCRC, Integrate interprofessional team-based approaches to improve patient adherence and education on prevention and management strategies for adverse events associated with third-line TKI-based therapies for mCRC.
Featuring perspectives from Prof Ghassan Abou-Alfa, Dr Richard Finn and Dr Robin Kelley, moderated by Dr Tanios Bekaii-Saab, including the following topics: Introduction (0:00) Advances in First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma (HCC) — Ghassan Abou-Alfa, MD, MBA (3:22) Selection and Sequencing of Therapy for Patients with Relapsed/Refractory HCC — Richard S Finn, MD (26:26) Current Treatment Strategies for Advanced Biliary Tract Cancers — Robin K Kelley, MD (46:53) Future Directions in the Management of Biliary Tract Cancer — Tanios Bekaii-Saab, MD (1:07:44) CME information and select publications
Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in acute myeloid leukemia, breast cancer, chronic lymphocytic leukemia and lymphomas, gastrointestinal cancers, genitourinary cancers, lung cancer and multiple myeloma. Featuring perspectives from Drs Neeraj Agarwal, Tanios Bekaii-Saab, Kristen Ciombor, Brad Kahl, Mark Levis, Ann Partridge, Mark Pegram, Daniel Petrylak, Noopur Raje, David Sallman, Lecia Sequist, David Spigel, Saad Zafar Usmani and Andrew Zelenetz.
Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in acute myeloid leukemia, breast cancer, chronic lymphocytic leukemia and lymphomas, gastrointestinal cancers, genitourinary cancers, lung cancer and multiple myeloma. Featuring perspectives from Drs Neeraj Agarwal, Tanios Bekaii-Saab, Kristen Ciombor, Brad Kahl, Mark Levis, Ann Partridge, Mark Pegram, Daniel Petrylak, Noopur Raje, David Sallman, Lecia Sequist, David Spigel, Saad Zafar Usmani and Andrew Zelenetz.
Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in acute myeloid leukemia, breast cancer, chronic lymphocytic leukemia and lymphomas, gastrointestinal cancers, genitourinary cancers, lung cancer and multiple myeloma. Featuring perspectives from Drs Neeraj Agarwal, Tanios Bekaii-Saab, Kristen Ciombor, Brad Kahl, Mark Levis, Ann Partridge, Mark Pegram, Daniel Petrylak, Noopur Raje, David Sallman, Lecia Sequist, David Spigel, Saad Zafar Usmani and Andrew Zelenetz.
Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in acute myeloid leukemia, breast cancer, chronic lymphocytic leukemia and lymphomas, gastrointestinal cancers, genitourinary cancers, lung cancer and multiple myeloma. Featuring perspectives from Drs Neeraj Agarwal, Tanios Bekaii-Saab, Kristen Ciombor, Brad Kahl, Mark Levis, Ann Partridge, Mark Pegram, Daniel Petrylak, Noopur Raje, David Sallman, Lecia Sequist, David Spigel, Saad Zafar Usmani and Andrew Zelenetz.
Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in acute myeloid leukemia, breast cancer, chronic lymphocytic leukemia and lymphomas, gastrointestinal cancers, genitourinary cancers, lung cancer and multiple myeloma. Featuring perspectives from Drs Neeraj Agarwal, Tanios Bekaii-Saab, Kristen Ciombor, Brad Kahl, Mark Levis, Ann Partridge, Mark Pegram, Daniel Petrylak, Noopur Raje, David Sallman, Lecia Sequist, David Spigel, Saad Zafar Usmani and Andrew Zelenetz.
Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in acute myeloid leukemia, breast cancer, chronic lymphocytic leukemia and lymphomas, gastrointestinal cancers, genitourinary cancers, lung cancer and multiple myeloma. Featuring perspectives from Drs Neeraj Agarwal, Tanios Bekaii-Saab, Kristen Ciombor, Brad Kahl, Mark Levis, Ann Partridge, Mark Pegram, Daniel Petrylak, Noopur Raje, David Sallman, Lecia Sequist, David Spigel, Saad Zafar Usmani and Andrew Zelenetz.
Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in acute myeloid leukemia, breast cancer, chronic lymphocytic leukemia and lymphomas, gastrointestinal cancers, genitourinary cancers, lung cancer and multiple myeloma. Featuring perspectives from Drs Neeraj Agarwal, Tanios Bekaii-Saab, Kristen Ciombor, Brad Kahl, Mark Levis, Ann Partridge, Mark Pegram, Daniel Petrylak, Noopur Raje, David Sallman, Lecia Sequist, David Spigel, Saad Zafar Usmani and Andrew Zelenetz.
Consensus or Controversy? Clinical Investigator Perspectives on the Current and Future Management of Hepatocellular Carcinoma and Pancreatic Cancer — Faculty Presentation 4: New Data Sets Investigating Novel Treatment Strategies for Advanced Biliary Tract Cancers — Dr Bekaii-Saab CME information and select publications
In the latest episode of "Oncology Peer Review On-The-Go," CancerNetwork examines a Q&A piece in the August issue of the journal ONCOLOGY discussing next-generation sequencing for gastrointestinal cancers. The article is titled “Ushering in the Era of Precision Medicine” and it focuses on a conversation with Tanios Bekaii-Saab, MD, of the Mayo Clinic in Phoenix, Arizona. For a responding perspective, CancerNetwork spoke with Howard Hochster, MD, of the Rutgers Cancer Institute of New Jersey. Dr. Hochster discussed his feelings regarding next-generation sequencing, and suggests alternative ways to treat patients with GI cancers. Don't forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.
Because cancer treatments can weaken the immune system, cancer patients are at increased risk of complications from COVID-19. Despite these concerns, cancer patients often still need treatment, including going to the clinic or to the hospital, and many have questions about whether cancer should be treated differently during the COVID-19 pandemic. On the Mayo Clinic Q&A podcast, Dr. Tanios Bekaii-Saab, a Mayo Clinic oncologist, explains how cancer patients can safely continue their cancer treatment during the pandemic.
Investigator Perspectives on the Current Utility of Validated and Emerging Biomarkers to Guide Treatment Decision-Making for Patients with Metastatic Colorectal Cancer. A roundtable discussion featuring Tanios Bekaii-Saab, MD and Alan P Venook, MD moderated by Neil Love, MD. Produced by Research To Practice.
Investigator Perspectives on the Current Utility of Validated and Emerging Biomarkers to Guide Treatment Decision-Making for Patients with Metastatic Colorectal Cancer. A roundtable discussion featuring Tanios Bekaii-Saab, MD and Alan P Venook, MD moderated by Neil Love, MD. Produced by Research To Practice.
Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Tanios Bekaii-Saab, MD, Professor, Mayo Clinic College of Medicine and Science, discuss biliary tract and GE junction cancer clinical highlights from ASCO GI 2019
Featuring key slides from the most important recent gastrointestinal cancer presentations and publications and video interviews with Dr Tanios Bekaii-Saab and Dr Eileen M O'Reilly. | For more information, visit: http://www.researchtopractice.com/YIROnDemand18/GI
Featuring key slides from the most important recent gastrointestinal cancer presentations and publications and video interviews with Dr Tanios Bekaii-Saab and Dr Eileen M O'Reilly. | For more information, visit: http://www.researchtopractice.com/YIROnDemand18/GI
Featuring key slides from the most important recent gastrointestinal cancer presentations and publications and video interviews with Dr Tanios Bekaii-Saab and Dr Eileen M O'Reilly. | For more information, visit: http://www.researchtopractice.com/YIROnDemand18/GI
Featuring key slides from the most important recent gastrointestinal cancer presentations and publications and video interviews with Dr Tanios Bekaii-Saab and Dr Eileen M O'Reilly. | For more information, visit: http://www.researchtopractice.com/YIROnDemand18/GI
Case-Based Discussions Focused on the Management of Metastatic Gastrointestinal Cancer. Featuring interviews with Philip A Philip, MD, PhD and Tanios Bekaii-Saab, MD conducted by Neil Love, MD. CME Information and Program PDF. Produced by Research To Practice.
Case-Based Discussions Focused on the Management of Metastatic Gastrointestinal Cancer. Interview with Tanios Bekaii-Saab, MD conducted by Neil Love, MD. Produced by Research To Practice.
Case-Based Discussions Focused on the Management of Metastatic Gastrointestinal Cancer. Featuring interviews with Philip A Philip, MD, PhD and Tanios Bekaii-Saab, MD conducted by Neil Love, MD. CME Information and Program PDF. Produced by Research To Practice.
Case-Based Discussions Focused on the Management of Metastatic Gastrointestinal Cancer. Interview with Tanios Bekaii-Saab, MD conducted by Neil Love, MD. Produced by Research To Practice.
Conversations with Oncology Investigators. Bridging the Gap between Research and Patient Care. Featuring interviews with Charles S Fuchs, MD, MPH, Tanios Bekaii-Saab, MD, Emily K Bergsland, MD and Josep Tabernero, MD conducted by Neil Love, MD. CME Information and Program PDF. Produced by Research To Practice.
Conversations with Oncology Investigators. Bridging the Gap between Research and Patient Care. Interview with Tanios Bekaii-Saab, MD conducted by Neil Love, MD. Produced by Research To Practice.
Conversations with Oncology Investigators. Bridging the Gap between Research and Patient Care. Featuring interviews with Charles S Fuchs, MD, MPH, Tanios Bekaii-Saab, MD, Emily K Bergsland, MD and Josep Tabernero, MD conducted by Neil Love, MD. CME Information and Program PDF. Produced by Research To Practice.
Conversations with Oncology Investigators. Bridging the Gap between Research and Patient Care. Interview with Tanios Bekaii-Saab, MD conducted by Neil Love, MD. Produced by Research To Practice.
Conversations with Oncology Investigators. Bridging the Gap between Research and Patient Care. Proceedings from a Clinical Investigator Think Tank featuring Tanios Bekaii-Saab, MD, Emily K Bergsland, MD, Charles S Fuchs, MD, MPH, Richard M Goldberg, MD, Axel Grothey, MD, Matthew Kulke, MD, MMSc, Bert H O'Neil, MD and Alan P Venook, MD. Moderated by Neil Love, MD. CME Information and Program PDF. Produced by Research To Practice.
Conversations with Oncology Investigators. Bridging the Gap between Research and Patient Care. Proceedings from a Clinical Investigator Think Tank featuring Tanios Bekaii-Saab, MD, Emily K Bergsland, MD, Charles S Fuchs, MD, MPH, Richard M Goldberg, MD, Axel Grothey, MD, Matthew Kulke, MD, MMSc, Bert H O'Neil, MD and Alan P Venook, MD. Moderated by Neil Love, MD. CME Information and Program PDF. Produced by Research To Practice.
Conversations with Oncology Investigators. Bridging the Gap between Research and Patient Care. Proceedings from a Clinical Investigator Think Tank featuring Tanios Bekaii-Saab, MD, Emily K Bergsland, MD, Charles S Fuchs, MD, MPH, Richard M Goldberg, MD, Axel Grothey, MD, Matthew Kulke, MD, MMSc, Bert H O'Neil, MD and Alan P Venook, MD. Moderated by Neil Love, MD. CME Information and Program PDF. Produced by Research To Practice.
Conversations with Oncology Investigators. Bridging the Gap between Research and Patient Care. Proceedings from a Clinical Investigator Think Tank featuring Tanios Bekaii-Saab, MD, Emily K Bergsland, MD, Charles S Fuchs, MD, MPH, Richard M Goldberg, MD, Axel Grothey, MD, Matthew Kulke, MD, MMSc, Bert H O'Neil, MD and Alan P Venook, MD. Moderated by Neil Love, MD. CME Information and Program PDF. Produced by Research To Practice.
Because cancer treatments can weaken the immune system, cancer patients are at increased risk of complications from COVID-19. Despite these concerns, cancer patients often still need treatment, including going to the clinic or to the hospital, and many have questions about whether cancer should be treated differently during the COVID-19 pandemic. On the Mayo Clinic Q&A podcast, Dr. Tanios Bekaii-Saab, a Mayo Clinic oncologist, explains how cancer patients can safely continue their cancer treatment during the pandemic. Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy
© 2020-2025 Ivy Podcast Discovery LLC
